-
Je něco špatně v tomto záznamu ?
Molecular monitoring of lung allograft health: is it ready for routine clinical use
P. Pradère, A. Zajacova, S. Bos, J. Le Pavec, A. Fisher
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 2013
Free Medical Journals
od 2005
PubMed Central
od 2010
Open Access Digital Library
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2005
- MeSH
- alografty MeSH
- imunosupresiva terapeutické užití MeSH
- lidé MeSH
- plíce * chirurgie MeSH
- rejekce štěpu diagnóza genetika prevence a kontrola MeSH
- transplantace plic * škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Maintenance of long-term lung allograft health in lung transplant recipients (LTRs) requires a fine balancing act between providing sufficient immunosuppression to reduce the risk of rejection whilst at the same time not over-immunosuppressing individuals and exposing them to the myriad of immunosuppressant drug side-effects that can cause morbidity and mortality. At present, lung transplant physicians only have limited and rather blunt tools available to assist them with this task. Although therapeutic drug monitoring provides clinically useful information about single time point and longitudinal exposure of LTRs to immunosuppressants, it lacks precision in determining the functional level of immunosuppression that an individual is experiencing. There is a significant gap in our ability to monitor lung allograft health and therefore tailor optimal personalised immunosuppression regimens. Molecular diagnostics performed on blood, bronchoalveolar lavage or lung tissue that can detect early signs of subclinical allograft injury, differentiate rejection from infection or distinguish cellular from humoral rejection could offer clinicians powerful tools in protecting lung allograft health. In this review, we look at the current evidence behind molecular monitoring in lung transplantation and ask if it is ready for routine clinical use. Although donor-derived cell-free DNA and tissue transcriptomics appear to be the techniques with the most immediate clinical potential, more robust data are required on their performance and additional clinical value beyond standard of care.
Institute of Transplantation Newcastle Upon Tyne Hospitals NHS Trust Newcastle Upon Tyne UK
Newcastle University Translational and Clinical Research Institute Newcastle upon Tyne UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000170
- 003
- CZ-PrNML
- 005
- 20240213093011.0
- 007
- ta
- 008
- 240109s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1183/16000617.0125-2023 $2 doi
- 035 __
- $a (PubMed)37993125
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Pradère, Pauline $u Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK p.pradere@ghpsj.fr $u Department of Respiratory Diseases, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph and Paris Saclay University, Paris, France $1 https://orcid.org/0000000340434666
- 245 10
- $a Molecular monitoring of lung allograft health: is it ready for routine clinical use / $c P. Pradère, A. Zajacova, S. Bos, J. Le Pavec, A. Fisher
- 520 9_
- $a Maintenance of long-term lung allograft health in lung transplant recipients (LTRs) requires a fine balancing act between providing sufficient immunosuppression to reduce the risk of rejection whilst at the same time not over-immunosuppressing individuals and exposing them to the myriad of immunosuppressant drug side-effects that can cause morbidity and mortality. At present, lung transplant physicians only have limited and rather blunt tools available to assist them with this task. Although therapeutic drug monitoring provides clinically useful information about single time point and longitudinal exposure of LTRs to immunosuppressants, it lacks precision in determining the functional level of immunosuppression that an individual is experiencing. There is a significant gap in our ability to monitor lung allograft health and therefore tailor optimal personalised immunosuppression regimens. Molecular diagnostics performed on blood, bronchoalveolar lavage or lung tissue that can detect early signs of subclinical allograft injury, differentiate rejection from infection or distinguish cellular from humoral rejection could offer clinicians powerful tools in protecting lung allograft health. In this review, we look at the current evidence behind molecular monitoring in lung transplantation and ask if it is ready for routine clinical use. Although donor-derived cell-free DNA and tissue transcriptomics appear to be the techniques with the most immediate clinical potential, more robust data are required on their performance and additional clinical value beyond standard of care.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a plíce $x chirurgie $7 D008168
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 12
- $a transplantace plic $x škodlivé účinky $7 D016040
- 650 _2
- $a alografty $7 D064591
- 650 _2
- $a rejekce štěpu $x diagnóza $x genetika $x prevence a kontrola $7 D006084
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Zajacova, Andrea $u Prague Lung Transplant Program, Department of Pneumology, Motol University Hospital and 2nd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Bos, Saskia $u Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK $u Institute of Transplantation, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, UK
- 700 1_
- $a Le Pavec, Jérôme $u Department of Respiratory Diseases, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph and Paris Saclay University, Paris, France
- 700 1_
- $a Fisher, Andrew $u Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK $u Institute of Transplantation, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, UK
- 773 0_
- $w MED00001661 $t European respiratory review $x 1600-0617 $g Roč. 32, č. 170 (2023)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37993125 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093008 $b ABA008
- 999 __
- $a ok $b bmc $g 2049078 $s 1209864
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 32 $c 170 $e 20231122 $i 1600-0617 $m European respiratory review $n Eur. respir. rev. $x MED00001661
- LZP __
- $a Pubmed-20240109